A practical reference on Heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-06 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Quantum dots are valued for displays because they emit light in very specific Gaussian distributions. This can result in a display with visibly more accurate colors. A conventional color liquid crystal display (LCD) is usually backlit by fluorescent lamps (CCFLs) or conventional white LEDs that are color filtered to produce red, green, and blue pixels. Quantum dot displays use blue-emitting LEDs rather than white LEDs as the light sources. The converting part of the emitted light is converted into pure green and red light by the corresponding color quantum dots placed in front of the blue LED or using a quantum dot infused diffuser sheet in the backlight optical stack. Blank pixels are also used to allow the blue LED light to still generate blue hues. This type of white light as the backlight of an LCD panel allows for the best color gamut at lower cost than an RGB LED combination using three LEDs. Another method by which quantum dot displays can be achieved is the electroluminescent (EL) or electro-emissive method. This involves embedding quantum dots in each individual pixel. These are then activated and controlled via an electric current application. Since this is often light emitting itself, the achievable colors may be limited in this method. Electro-emissive QD-LED TVs exist in laboratories only. The ability of QDs to precisely convert and tune a spectrum makes them attractive for LCDs. Previous LCDs can waste energy converting red-green poor, blue-yellow rich white light into a more balanced lighting.
=== Disappearance === On 4 March 1998, at around 2:00 PM, Mendonça took his bicycle and cycled to his mother's workplace, located near the family home. He had asked his mother for permission to spend the afternoon riding in a car "with his friend Afonso" (Afonso Dias), a 22-year-old lorry driver. Mendonça's mother denied the request, and told him to go play in an abandoned lot outside her office.
== Clinical significance == Polymorphisms in ACTC1 have been linked to dilated cardiomyopathy in a small number of Japanese patients. Further studies in patients from South Africa found no association. The E101K missense mutation has been associated with hypertrophic cardiomyopathy and left ventricular noncompaction. Another mutation has in the ACTC1 gene has been associated with atrial septal defects.
According to scholar Shirley Anne Tate, skin whiteners in the United States were initially predominantly used by white women. European immigrants introduced recipes for cosmetic skin lighteners into the American colonies, where they eventually evolved to incorporate indigenous and West African herbal traditions. Skin whitening grew in popularity in the 1800s, as white women in the United States began to emulate the skin-whitening practices performed by those in Europe. As such, American women similarly used ceruse, arsenic wafers, and products that contained toxic dosages of lead and mercury. Mormon denominations, like the Church of Jesus Christ of Latter-day Saints (LDS church), taught into the 1970s that God would whiten the skin color of Native American adherents, and that skin color was correlated with premortal obedience to God. In the 2015 book, Skin bleaching in Black Atlantic zones: shade shifters, author Shirley Anne Tate writes that skin lightening was often not well-received in Black culture. Women in Black cultures who used skin whiteners were described as artificial, while Black men who used skin whiteners were described as overly effeminate. Despite this reception, skin whitening remained a popular practice. Historians note that advertisements for skin whiteners in the 20th century often associated pale skin with gentility. According to historian Kathy Peiss, skin whitening among black American women had been documented starting in the mid-nineteenth century.
Sources: en.wikipedia.org
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase is an enzyme that in humans is encoded by the MGAT1 gene. There are over 100 different glycosyltransferases involved in the synthesis of protein-bound and lipid-bound oligosaccharides. UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I is a medial-Golgi enzyme essential for the synthesis of hybrid and complex N-glycans. The protein, encoded by a single exon, shows typical features of a type II transmembrane protein. The protein is believed to be essential for normal embryogenesis.
1,4-Dimethylamylamine (1,4-DMAA), also known as 1,4-dimethylpentylamine or as 5-methylhexan-2-amine, is a stimulant drug of the alkylamine family related to methylhexanamine (1,3-DMAA; geranamine). It is naturally present in geranium plants and has also been found in certain other plants. 1,4-DMAA has been identified in dietary supplements. It produces sympathomimetic effects in animals and humans. 1,4-DMAA and other alkylamine stimulants may act as catecholamine releasing agents. Unlike octodrine and methylhexanamine, 1,4-DMAA has never been used as a pharmaceutical drug.
=== Water === In 1998, perchlorate was included in the U.S. EPA Contaminant Candidate List, primarily due to its detection in California drinking water. In 2002, the EPA completed its draft toxicological review of perchlorate and proposed a reference dose of 0.00003 milligrams per kilogram per day (mg/kg/day) based primarily on studies that identified neurodevelopmental deficits in rat pups. These deficits were linked to maternal exposure to perchlorate. In 2003, a federal district court in California found that the Comprehensive Environmental Response, Compensation and Liability Act applied, because perchlorate is ignitable, and therefore was a "characteristic" hazardous waste. Subsequently, the U.S. National Research Council of the National Academy of Sciences (NAS) reviewed the health implications of perchlorate, and in 2005 proposed a much higher reference dose of 0.0007 mg/kg/day based primarily on a 2002 study by Greer et al. During that study, 37 adult human subjects were split into four exposure groups exposed to 0.007 (7 subjects), 0.02 (10 subjects), 0.1 (10 subjects), and 0.5 (10 subjects) mg/kg/day. Significant decreases in iodide uptake were found in the three highest exposure groups. Iodide uptake was not significantly reduced in the lowest exposed group, but four of the seven subjects in this group experienced inhibited iodide uptake. In 2005, the RfD proposed by NAS was accepted by EPA and added to its integrated risk information system (IRIS).
==== De novo motif discovery ==== There are software programs which, given multiple input sequences, attempt to identify one or more candidate motifs. One example is the Multiple EM for Motif Elicitation (MEME) algorithm, which generates statistical information for each candidate. There are more than 100 publications detailing motif discovery algorithms; Weirauch et al. evaluated many related algorithms in a 2013 benchmark. The planted motif search is another motif discovery method that is based on combinatorial approach.
==== Saudi Arabia ==== On 15 August 2012 at 11:08 am local time, the Shamoon virus began destroying over 35,000 computer systems, rendering them inoperable. The virus used to target the Saudi government by causing destruction to the state owned national oil company Saudi Aramco. The attackers posted a pastie on PasteBin.com hours prior to the wiper logic bomb occurring, citing oppression and the Al-Saud regime as a reason behind the attack. The attack was well staged according to Chris Kubecka, a former security advisor to Saudi Aramco after the attack and group leader of security for Aramco Overseas. It was an unnamed Saudi Aramco employee on the Information Technology team which opened a malicious phishing email, allowing initial entry into the computer network around mid-2012. Kubecka also detailed in her Black Hat USA talk Saudi Aramco placed the majority of their security budget on the ICS control network, leaving the business network at risk for a major incident. The virus has been noted to have behavior differing from other malware attacks, due to the destructive nature and the cost of the attack and recovery. US Defense Secretary Leon Panetta called the attack a "Cyber Pearl Harbor". Shamoon can spread from an infected machine to other computers on the network. Once a system is infected, the virus continues to compile a list of files from specific locations on the system, upload them to the attacker, and erase them. Finally the virus overwrites the master boot record of the infected computer, making it unusable.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.